GCA management guidelines - vive la différence?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026
   Review
2. A Machine Learning Model Based on Radiomic Features as a Tool to Identify Active Giant Cell Arteritis on [Diagnostics (Basel, Switzerland) · 2025
   Article
3. [Granulomatous vasculitides and vasculitides with extravascular granulomatosis].Zeitschrift fur Rheumatologie · 2022
   Review
4. [Biologics for connective tissue diseases and vasculitides].Der Internist · 2022
   Review

Corrections and comments

• Comment on
  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.